24 completed, 4 terminated, 3 unknown, 1 withdrawn. 11 Phase 3, 9 Phase 4, 5 Not applicable, 5 Phase 2, 2 Phase 1.
Follow sibutramine: new trials by email Literature Review of sibutramine trials Research Report on sibutramine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Retrospective Evaluation of Sibutramine-Topiramate Therapy for Obesity in Real-World Outpatient Practice Sibutramine + Topiramate - Obesity & Overweight | Completed | Falquetomed | 278 | 2026-06-01 | 2026-09-02 | |
| A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg, ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg, SIB Group Sibus (Sibutramine) 15mg - Overweight, Obesity | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-04-01 | 2025-12-18 | |
| Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine Sibutramine, Orlistat - Obesity | Not applicable | Completed | Gachon University Gil Medical Center | 174 | 2010-02-01 | 2010-08-19 |
| Effects of Weight Loss in Obese Difficult-to-treat Asthmatics Low caloric diet plus orlistat and sibutramine - Asthma, Obesity | Phase 3 | Completed | University of Sao Paulo General Hospital | 33 | 2009-11-01 | 2011-02-23 |
| A Weight Loss Study in Overweight Men and Women LY377604, Sibutramine, Metoprolol - Obesity | Phase 2 | Terminated | Eli Lilly and Company | 343 | 2009-10-01 | 2011-06-03 |
| A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103) Placebo, Comparator: sibutramine - Obesity | Phase 1 | Completed | Merck Sharp & Dohme LLC | 15 | 2009-05-01 | 2015-10-12 |
| "Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention" Sibutramine - Obesity | Not applicable | Unknown | Brooke Army Medical Center | 100 | 2009-04-01 | 2009-12-02 |
| Studying the Effects of Sibutramine on Eating Behavior Sibutramine, Placebo - Obesity | Phase 4 | Terminated | New York State Psychiatric Institute | 14 | 2009-02-01 | 2017-08-30 |
| Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients Sibutramine-Metformin, Sibutramine, Metformin - Obesity | Phase 3 | Unknown | Laboratorios Silanes S.A. de C.V. | 60 | 2008-11-01 | 2009-07-17 |
| Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care Behavioral Weight Loss, Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy, Placebo - Obesity, Binge Eating | Not applicable | Completed | Yale University | 191 | 2008-11-01 | 2020-04-03 |
| A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects sibutramine, sibutramine placebo - Obesity | Phase 1 | Completed | GlaxoSmithKline | 60 | 2008-05-22 | 2017-06-20 |
| A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects Nasal Placebo, Placebo Capsule, PYY3-36 - Obesity | Phase 2 | Completed | Nastech Pharmaceutical Company, Inc. | 551 | 2007-10-01 | 2008-09-15 |
| Treatment of Binge Eating in Obese Patients in Primary Care Sibutramine, Placebo, Self-help CBT + Sibutramine - Obesity, Binge Eating | Phase 4 | Completed | Yale University | 104 | 2007-09-01 | 2021-08-18 |
| A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects pramlintide acetate, sibutramine, phentermine - Overweight, Obesity | Phase 2 | Completed | AstraZeneca | 258 | 2006-11-01 | 2015-03-06 |
| Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes sibutramine - Obesity | Phase 4 | Completed | Mayo Clinic | 181 | 2006-07-01 | 2011-03-14 |
| LOSS- Louisiana Obese Subjects Study group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One - Obesity | Phase 4 | Terminated | Pennington Biomedical Research Center | 390 | 2005-07-01 | 2016-02-22 |
| A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects CP-945,598, sibutramine - Obesity | Phase 2 / Phase 3 | Completed | Pfizer | 282 | 2005-03-01 | 2009-08-12 |
| Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity sibutramine - Obesity, Overweight | Phase 2 | Completed | Mayo Clinic | 72 | 2005-01-01 | 2010-01-20 |
| A Comparative Study of KES524 in Patients With Obesity Disease Sibutramine Hydrochloride Monohydrate - Obesity | Phase 3 | Completed | Eisai Limited | 2004-07-01 | 2010-01-29 | |
| A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects. sibutramine hydochloride monohydrate - Obesity | Phase 4 | Completed | Abbott | 93 | 2004-06-01 | 2008-07-15 |
Showing 20 of 32. Sign in to see all of them.
Obesity (30) · Overweight (4) · Weight Loss (4) · Bulimia (2) · Hypertension (2) · Asthma (1) · Binge-Eating Disorder (1) · Bipolar Disorder (1) · Cardiovascular Diseases (1) · Feeding Behavior (1) · Heart Diseases (1) · Insulin Resistance (1) · Polycystic Ovary Syndrome (1) · Psychotic Disorders (1) · Schizophrenia (1)
Abbott (7) · Eli Lilly and Company (2) · Mayo Clinic (2) · Yale University (2) · Aristotle University Of Thessaloniki (1) · AstraZeneca (1) · Brooke Army Medical Center (1) · Eisai Limited (1) · Eurofarma Laboratorios S.A. (1) · Falquetomed (1) · Gachon University Gil Medical Center (1) · GlaxoSmithKline (1) · Hippocration General Hospital (1) · Laboratorios Silanes S.A. de C.V. (1) · Laval University (1)
United States (15) · Brazil (3) · Greece (2) · Japan (1) · Mexico (1) · South Korea (1) · United Kingdom (1)
Alberto Cukier, PhD (1) · Carlos M Grilo, PhD (1) · Carlos M. Grilo, PhD (1) · Cheryl Renz, MD (1) · Dimitrios Panidis, PhD (1) · Dimos Florakis, MD (1) · Donna H Ryan, MD (1) · Gordon Brandt, M.D. (1) · Jorge L Cabrera, MD, PhD (1) · Karen C. Johnson, MD, MPH (1)
PMID 10102256, PMID 15536230, PMID 16847290, PMID 17576783, PMID 18056225, PMID 18725220, PMID 19357147, PMID 19828038, PMID 20101009, PMID 20184783, PMID 20818901, PMID 20948512, PMID 21151016, PMID 21962313, PMID 23061407, PMID 24262967, PMID 24406481, PMID 24411757, PMID 24534073, PMID 24857821, PMID 25280441, PMID 25622201, PMID 26214545, PMID 32985114, PMID 38321617, PMID 40691810
R01DK049587 (1), R01DK073542 (1), R01HL068049 (1)